We have located links that may give you full text access.
Journal Article
Review
Migraine Headache: Updates and Future Developments.
Mayo Clinic Proceedings 2018 November
Migraine is a common disabling condition that is frequently managed by primary care providers. In recent years, the growing array of migraine therapies has added complexity to patient care. This article serves as a succinct review of pertinent updates and future directions regarding migraine. Our understanding of pathophysiology has progressed along with new advances in biomarkers and genetics. These discoveries have led to a wealth of new options for treatment, many of which are specifically targeted against molecules implicated in migraine headache such as calcitonin gene-related peptide. These treatments include several monoclonal antibodies, calcitonin-gene related peptide receptor antagonists, and 5-hydroxytryptamine 1F (5-HT1F) receptor agonists; new options such as these are important for the large population falling out of eligibility for triptans. Furthermore, various nonpharmacological options including noninvasive brain stimulation have joined the arsenal of therapies used for treating migraine.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app